CRIS Current Research Information System

BRANDI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.211
AS - Asia 15.689
EU - Europa 10.281
AF - Africa 895
SA - Sud America 846
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 11
AN - Antartide 1
Totale 43.953
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.033
VN - Vietnam 4.460
SG - Singapore 4.380
CN - Cina 3.779
GB - Regno Unito 2.258
IT - Italia 1.555
DE - Germania 1.312
SE - Svezia 1.228
HK - Hong Kong 991
IN - India 723
FR - Francia 703
RU - Federazione Russa 610
BR - Brasile 580
IE - Irlanda 566
CH - Svizzera 460
UA - Ucraina 336
KR - Corea 302
NL - Olanda 302
FI - Finlandia 298
JP - Giappone 247
ZA - Sudafrica 228
CI - Costa d'Avorio 192
TG - Togo 179
EE - Estonia 159
SC - Seychelles 137
ID - Indonesia 108
JO - Giordania 105
AR - Argentina 102
CA - Canada 101
PH - Filippine 92
AT - Austria 90
BG - Bulgaria 89
TH - Thailandia 70
NG - Nigeria 66
BE - Belgio 63
IQ - Iraq 60
BD - Bangladesh 57
PL - Polonia 52
TR - Turchia 50
MX - Messico 49
GR - Grecia 40
TW - Taiwan 39
CL - Cile 38
PK - Pakistan 38
EC - Ecuador 37
ES - Italia 32
MY - Malesia 28
CO - Colombia 27
SA - Arabia Saudita 26
PY - Paraguay 24
HR - Croazia 22
IR - Iran 22
UZ - Uzbekistan 21
LT - Lituania 20
RO - Romania 20
VE - Venezuela 18
AU - Australia 15
MA - Marocco 15
PS - Palestinian Territory 14
AE - Emirati Arabi Uniti 13
EG - Egitto 13
PE - Perù 12
ET - Etiopia 11
LB - Libano 11
TN - Tunisia 11
CZ - Repubblica Ceca 10
KZ - Kazakistan 10
PT - Portogallo 10
DZ - Algeria 9
CR - Costa Rica 8
KE - Kenya 8
AZ - Azerbaigian 7
DK - Danimarca 7
NP - Nepal 7
A2 - ???statistics.table.value.countryCode.A2??? 6
GH - Ghana 6
SI - Slovenia 6
AL - Albania 5
HU - Ungheria 5
JM - Giamaica 5
UY - Uruguay 5
IL - Israele 4
NO - Norvegia 4
OM - Oman 4
SN - Senegal 4
AO - Angola 3
BO - Bolivia 3
GE - Georgia 3
LK - Sri Lanka 3
LV - Lettonia 3
NZ - Nuova Zelanda 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BH - Bahrain 2
BY - Bielorussia 2
CG - Congo 2
Totale 43.910
Salva come PNG Salva come JPEG
Città #
Singapore 3.006
Southend 1.985
Ashburn 1.553
Chandler 1.325
Fairfield 1.286
San Jose 970
Hong Kong 931
Ho Chi Minh City 915
Dong Ket 832
Hanoi 799
Santa Clara 711
Dallas 671
Princeton 632
Wilmington 600
Houston 599
Hefei 592
Woodbridge 578
Seattle 537
Dublin 516
Beijing 511
Bern 438
Cambridge 424
Boardman 386
Bologna 377
Ann Arbor 368
Lauterbourg 312
Los Angeles 251
Helsinki 242
Seoul 234
New York 228
Council Bluffs 221
Tokyo 213
Nanjing 208
Westminster 201
Abidjan 192
Jacksonville 192
Lomé 179
Padova 170
Berlin 151
Jinan 129
Da Nang 122
Redondo Beach 122
San Diego 120
Haiphong 117
Buffalo 115
Frankfurt am Main 115
Milan 114
Menlo Park 112
Amman 102
Medford 98
Saint Petersburg 95
Guangzhou 94
Shenyang 92
Redmond 88
Sofia 85
Shanghai 83
Changsha 80
Hebei 77
São Paulo 73
Turin 70
Jakarta 68
Florence 64
Chicago 63
Nanchang 63
Rome 62
Brussels 58
Mülheim 57
Bengaluru 56
Nuremberg 55
London 53
Tianjin 53
Munich 52
Vienna 51
Jiaxing 49
Zhengzhou 46
Abeokuta 45
Des Moines 43
Orem 42
Hangzhou 41
Toronto 41
Can Tho 40
Amsterdam 39
Yubileyny 39
Hải Dương 37
Redwood City 37
Biên Hòa 36
Dearborn 35
Lappeenranta 35
Olalla 34
Brooklyn 33
Montreal 33
Ninh Bình 33
Warsaw 33
Pune 32
Kuban 31
Norwalk 31
The Dalles 31
Bremen 30
Bühl 29
Johannesburg 29
Totale 28.378
Salva come PNG Salva come JPEG
Nome #
Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis 396
Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms 390
Adjuvant treatment in biliary tract cancer 341
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 301
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 296
Genome-wide analysis identifies MEN1 and MAX mutations and a neuroendocrine-like molecular heterogeneity in Quadruple WT GIST 277
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 276
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. 261
Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. 259
Adjuvant chemotherapy for resected colorectal cancer metastases: literature revision and meta-analysis 259
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. 254
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. 248
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 246
Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation 246
Antiprotease strategy in combination with gemcitabine as a putative novel therapeutic approach for pancreatic cancer treatment 245
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 245
An atlas for clinical target volume definition, including elective nodal irradiation in definitive radiotherapy of biliary cancer 241
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 238
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 236
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 234
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report 230
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib. 226
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 225
Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST) 221
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 216
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 216
Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer:A literature review and report of two cases 215
Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. 215
Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. 215
Evolving knowledge in surgical oncology of pancreatic cancer: from theory to clinical practice-a fifteen-year journey at a tertiary referral centre 213
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients? 210
Asbestos: a putative risk factor for intrahepatic cholangiocarcinoma 209
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention 209
Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. 208
Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis 208
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer 207
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 207
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 207
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience. 205
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 205
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST) 204
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 204
HIV enteropathy: undescribed ultrastructural changes of duodenal mucosa and their regression after triple antiviral therapy. A case report 203
219 MiR-21 expression correlates with prognosis in extrahepatic radically resected cholangiocarcinomas treated with gemcitabine-based adjuvant chemotherapy 203
An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor 203
Cell proliferation and ultrastructural changes of the duodenal mucosa of patients affected by familial adenomatous polyposis. 201
Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases. 200
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 200
Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. 199
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 198
Bone metastases in biliary cancers: A multicenter retrospective survey 196
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 196
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 195
Risk of duodenal adenomas in familial adenomatous polyposis to progress toward advanced neoplastic disease 195
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 194
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 194
In Reply 188
ACTIVATED NF-KB IN COLORECTAL CANCER: PREDICTIVE OR PROGNOSTIC FACTOR? 186
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 184
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 184
Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: Correlations with cholangiocarcinoma aggressiveness 183
Treatment of colorectal cancer liver metastases 180
Second-line chemotherapy in patients with biliary tract cancer. 178
Searching for novel multimodal treatments in oligometastatic pancreatic cancer 178
Urease-Positive Bacteria Other than Helicobacter pylori in Human Gastric Juice and Mucosa 177
A multicenter survey on second-line chemotherapy for advanced biliary tract cancer 177
Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. 177
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 176
Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. 175
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 175
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies 174
Breast carcinoma presenting as linitis plastica 173
Cholangiocarcinoma: Epidemiology and risk factors 173
Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice 172
Cholangiocarcinoma: From risk to prevention? 172
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma 171
Interactions between commensal bacteria and gut sensorimotor function in health and disease. 171
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 171
BIFIDOBACTERIACEAE IN THE ACHLORIDRIC STOMACH 170
Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries 169
Molecular imaging suggests efficacy of bevacizumab beyond the second line in advanced colorectal cancer patients. 167
Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. 167
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. 167
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 166
Capecitabine(CAP) based regimens vs infusional 5FU/AF in metastatic colorectal cancer cost/effectivness: the differences across the atlantic ocean 166
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 166
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study 166
Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma 165
null 164
EXPOSURE TO ASBESTOS: A PUTATIVE UNKNOWN RISK FACTOR FOR INTRAHEPATIC CHOLANGIOCARCINOMA 164
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 164
Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review 163
KRAS and BRAF mutational status as selective criteria for targeted therapy in cholangiocarcinoma. 163
Bifidobacteriaceae usually colonize human hypochloridric stomach 162
Chemotherapy in Patients with Advanced Cholangiocarcinoma 162
The Protease Inhibitor Gabexate Mesylate Reduces Invasiveness and Angiogenesis in Pancreatic Cancer Cell Lines, Enhancing Gemcitabine Action 161
Impact of adjuvant chemotherapy on time to relapse in cholangiocarcinoma. 159
Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS) 159
Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement 157
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 157
Totale 20.440
Salva come PNG Salva come JPEG
Categoria #
all - tutte 127.113
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.113
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.637 0 0 0 0 0 0 0 0 0 141 157 1.339
2021/20225.044 417 188 242 325 378 226 167 285 483 312 1.165 856
2022/20236.053 657 805 311 671 399 445 190 349 977 214 423 612
2023/20241.582 193 264 113 135 111 330 73 83 51 103 58 68
2024/20256.393 252 1.036 642 501 1.031 304 443 173 104 421 280 1.206
2025/202615.539 1.540 1.473 1.889 1.167 1.651 884 1.777 773 3.267 1.118 0 0
Totale 44.959